Optic nerve

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Stomach, Interferon beta-1a, ATC, Pain, Multiple sclerosis, Capsule, International, RRMS, Spinal cord, Disease, PML, Ageing, Nausea, Language, Brain, Mouth, Eye, Inflammation, Flushing, European Medicines Agency, Food, Gene, Glatiramer acetate, Select, Central nervous system, Patient, Safety, Encephalitis, Anatomy, Sclerosis, Optic nerve, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
IOP, Medical Subject Headings, Marketing, Pupil, INN, ATC, Paratriathlon, Bleeding, International, Drainage, Iris, Ocular hypertension, Disease, Language, Brain, Eye, Timolol, European Medicines Agency, Select, Rho, Patient, Vein, Safety, Anatomy, Retina, IIA, Pressure, Optic nerve, Erythema, Medical device

Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 3, Status: Authorised

Delta Dental of Tennessee Launches Annual Holiday Campaign With $75,000 Pledge to Children's Hospitals Across Tennessee

Retrieved on: 
Tuesday, November 21, 2023
Other Philanthropy, General Health, Family, Consumer, Preschool, Optical, Teens, Parenting, Children, Hospitals, Health Insurance, Communications, Dental, Philanthropy, Social Media, Health, Fund Raising, Primary, Secondary, Foundation, Education, Eye, Organization, Volleyball, Glaucoma, Delta Dental, Multimedia, Delta, Calendar, Heart, Social media, Friends, Child, MD, Diagnosis, Lynch, Doctor of Philosophy, MRI, Parent, Hospital, Optic nerve, Paratriathlon, Health insurance, Nursing, Toy

Delta Dental of Tennessee (Delta Dental) today launched its annual holiday campaign, pledging a collective $75,000 in donations to the seven children’s hospitals across the state.

Key Points: 
  • Delta Dental of Tennessee (Delta Dental) today launched its annual holiday campaign, pledging a collective $75,000 in donations to the seven children’s hospitals across the state.
  • Delta Dental of Tennessee is the state’s largest independent dental benefits carrier with 1.4 million lives covered.
  • As part of the Delta Dental Plans Association, Delta Dental of Tennessee members have access to the largest dental network in the nation with more than 154,000 providers serving more than 443,000 locations.
  • With the simple mission of ensuring healthy smiles, Delta Dental of Tennessee works hard to help members of the communities it serves.

Prevent Blindness Declares Fourth Annual Thyroid Eye Disease Awareness Week as Nov. 13-19, 2023

Retrieved on: 
Thursday, November 9, 2023
Well, UCHealth, Social media, Health, Optic nerve, Sue, Balance: Television for Living Well, Neuro, MD, Doctor of Philosophy, Inflammation, Blinking, Mental, Graves' ophthalmopathy, Visual impairment, Quality of life, Eyelid, Tissue, Immune system, TED, Paratriathlon, Autoimmune disease, Swelling, Eye, Depression, Anxiety, Therapy, Patient, Diagnosis, Communication, Mental health, Pharmaceutical industry, Nursing, Ophthalmology, Amgen

CHICAGO, Nov. 9, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, has declared Nov. 13-19, 2023, as its fourth annual "Thyroid Eye Disease Awareness (TED) Week." TED, also known as Graves' Eye Disease, is an autoimmune disease in which the immune system causes inflammation and swelling and stimulates the production of muscle tissue and fat behind the eye.

Key Points: 
  • Prevent Blindness provides free educational materials on Thyroid Eye Disease, including new Focus on Eye Health Export series episode, and debuts online art gallery from participants in the Prevent Blindness Art Therapy program
    CHICAGO, Nov. 9, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health and safety organization, has declared Nov. 13-19, 2023, as its fourth annual "Thyroid Eye Disease Awareness (TED) Week."
  • TED, also known as Graves' Eye Disease, is an autoimmune disease in which the immune system causes inflammation and swelling and stimulates the production of muscle tissue and fat behind the eye.
  • Because many individuals with TED are more likely to develop depression and anxiety , during TED Awareness Week, Prevent Blindness will also debut a new episode in the Focus on Eye Health Expert Series , "Thyroid Eye Disease and Mental Wellness."
  • "Now in our 4th consecutive year, we are proud to continue to educate the public and provide patients and care partners with support for Thyroid Eye Disease," said Jeff Todd, Prevent Blindness president and CEO.

Stuart Therapeutics Announces Exclusive Worldwide License Agreement with Glaukos Corporation

Retrieved on: 
Wednesday, October 18, 2023
Therapy, Extracellular matrix, Research, Axon, Neuroprotection, Patient, Intraocular pressure, Optic nerve, Glaucoma, Pharmaceutical industry

STUART, Fla., Oct. 18, 2023 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart") today announced that it has entered into a license agreement with Glaukos Corporation ("Glaukos") under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113 drug candidate for neuroprotection in glaucoma.

Key Points: 
  • STUART, Fla., Oct. 18, 2023 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart") today announced that it has entered into a license agreement with Glaukos Corporation ("Glaukos") under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113 drug candidate for neuroprotection in glaucoma.
  • Under the agreement, Stuart will receive an upfront payment, and is eligible for additional development and sales related milestone payments, plus royalties.
  • They bring critical focus on novel therapies, capabilities in drug product design and delivery, and commercial strength worldwide.
  • Stuart Therapeutics is proud to work with Glaukos on this important program," said Eric Schlumpf, President and Chief Executive Officer of Stuart.

InventHelp Inventor Develops New Glaucoma Pillow (RKH-533)

Retrieved on: 
Wednesday, October 11, 2023
Pressure, Intraocular pressure, Multimedia, Risk, DEPT, Humour, Glaucoma, Optic nerve, Suite, Sale, Pharmaceutical industry

PITTSBURGH, Oct. 11, 2023 /PRNewswire/ -- "I'm an optometrist and I wanted to create a pillow to lower intraocular pressure while sleeping," said an inventor, from Nokesville, Va., "so I invented the GLAUCOMA PILLOW.

Key Points: 
  • PITTSBURGH, Oct. 11, 2023 /PRNewswire/ -- "I'm an optometrist and I wanted to create a pillow to lower intraocular pressure while sleeping," said an inventor, from Nokesville, Va., "so I invented the GLAUCOMA PILLOW.
  • My design could be employed to help control or reduce the risk of glaucoma."
  • The patent-pending invention provides an improved pillow to help reduce intraocular pressure.
  • 21-RKH-533, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

Retrieved on: 
Wednesday, October 4, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Contact, Ernest, Cerebral edema, Palace, Employment, Pain, Telecanthus, Incidence, Hilton New Orleans Riverside, Steroid, Viral, Macular edema, Herpes simplex, NYSE, Chickenpox, Magazine Street, Canal Street, Conjunctiva, EYE, Tchoupitoulas Street, Risk, Pigment, Intraocular pressure, SM, Optic nerve, FDA, INA War Museum, Iris, Andhra Pradesh Decentralisation and Inclusive Development of All Regions Act, 2020, Fungal infection, Poydras Street, Sclera, Eye, Bausch, History, Slit lamp, Glaucoma, Ocular hypertension, DED, Cornea, IOP, Contact lens, Infection, American Academy, Inflammation, Johnson & Johnson Vision, Vaccinia, Bausch & Lomb, Lens (vertebrate anatomy), Visual acuity, Pharmaceutical industry, Medical device, Hospital, Telescopic sight, Hotel, Gasoline, Nursing, Dietary supplement, Vaccine, Blinking, O.D, Patient

Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.

Key Points: 
  • Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.
  • Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios.
  • The Bausch + Lomb schedule at AAOpt:
    “Clinical Dry Eye Findings in Patients Using a Novel Lipid-Containing Eye Drop.” Joshi et al.
  • “Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Reduces Corneal Staining Across All Regions of the Cornea.” Fahmy et al.

The MOG Project, Pediatric Neurologist Secure CDC Approval to Adopt ICD-10 Code for Rare Disease MOGAD

Retrieved on: 
Monday, October 2, 2023
Insurance, Optic neuritis, General assembly, Disease, United Nations, Glycoprotein, CHLA, Neuroimmunology, ICD, Lou Ruvo Center for Brain Health, Knowledge Organization (journal), United Nations General Assembly, Centers for Disease Control and Prevention, Research, Brain, Children's Hospital, Multiple sclerosis, CDC, MOGAD, MD, Patient, Physician, Children's Hospital Los Angeles, Immune system, Optic nerve, Stockholm Environment Institute US Center, Transverse myelitis, Diagnosis, Knowledge, Neuromyelitis optica spectrum disorder, Barrow Neurological Institute, International Classification of Diseases, Video game–related health problems, FDA, Acute disseminated encephalomyelitis, WHO, World Health Organization, Medical device

OLNEY, Md., Oct. 2, 2023 /PRNewswire-PRWeb/ -- The MOG Project, a nonprofit organization committed to supporting the research and treatment of Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) announced that its Executive Director Julia Lefelar, with support from The MOG Project Executive Board and Children's Hospital Los Angeles (CHLA) Pediatric Neurologist Jonathan Santoro, MD, secured approval to have the US Centers for Disease Control and Prevention (CDC) create an ICD-10 code for MOGAD. As of October 1, 2023, an official code for MOGAD is included in the 10th edition of the International Classification of Diseases (ICD) and Related Health Problems, which is relied upon by physicians and insurance providers to classify diagnoses and advise treatment.

Key Points: 
  • Without a CDC code, MOGAD patients had previously been grouped in with patients with similar diseases like neuromyelitis optica spectrum disorder, optic neuritis, acute disseminated encephalomyelitis, transverse myelitis and even multiple sclerosis.
  • "For the MOGAD community, this CDC code is more than a win for better health outcomes and fewer insurance delays, it gives our rare disease an identity and legitimizes it."
  • "The addition of a MOGAD specific ICD-10 code allows patients to better access the therapies that they need to treat their disease," said Santoro.
  • "Further, it allows for disease monitoring across the country, which will increase knowledge and research on this rare neuroimmunology disorder."

Globally Recognized Expert in Rare Neurologic Diseases, Dr. Michael Levy, Joins Trethera Scientific Advisory Board

Retrieved on: 
Tuesday, September 5, 2023
Demyelinating disease, DSM-IV codes, Optic neuritis, Central nervous system, University, Johns Hopkins Hospital, Myelin, Spinal cord, Cancer, Coronavirus Scientific Advisory Board, American Academy, Brain, Inflammation, Multiple sclerosis, Doctor of Philosophy, Associate, MS, Harvard Medical School, Nerve, CNS demyelinating autoimmune diseases, Patient, Division, Optic nerve, ADEM, Baylor College of Medicine, Hospital, Massachusetts General Hospital, American Academy of Neurology, Acute disseminated encephalomyelitis, Peripheral nervous system, Pharmaceutical industry, Philosophy, MD, Neurology

Dr. Levy will have a particular focus on evaluating the clinical development of Trethera’s lead asset, TRE-515, in demyelinating autoimmune diseases.

Key Points: 
  • Dr. Levy will have a particular focus on evaluating the clinical development of Trethera’s lead asset, TRE-515, in demyelinating autoimmune diseases.
  • When the myelin sheath is damaged, nerve impulses slow or even stop, causing neurological problems.
  • “We are honored to have Dr. Levy join our advisory board,” said Dr. Ken Schultz, Chairman and CEO of Trethera.
  • “He is a leading authority on rare neurologic autoimmune diseases and has expertise in both early and late-stage clinical trials.

Dr. Parul Khator Becomes First Doctor In Georgia to Use the iTrack Advance Canaloplasty Device for Glaucoma

Retrieved on: 
Tuesday, August 29, 2023
Medical Devices, Health, Health Technology, General Health, Optical, Biotechnology, Infection, Tunnel, Glaucoma, Injury, IOP, Surgeon, Headache, Trabecular meshwork, Visual impairment, Paratriathlon, Inflammation, MIGS, Intraocular pressure, Angioplasty, Patient, Risk, Humour, Optic nerve, Hospital

Georgia Eye Partners is proud to share that Dr. Parul Khator has become the first eye surgeon in Georgia to utilize the iTrack Advance Canaloplasty Device, a minimally invasive glaucoma surgical device (MIGS) used to reduce intraocular pressure (IOP) in adult patients with primary open-angle glaucoma.

Key Points: 
  • Georgia Eye Partners is proud to share that Dr. Parul Khator has become the first eye surgeon in Georgia to utilize the iTrack Advance Canaloplasty Device, a minimally invasive glaucoma surgical device (MIGS) used to reduce intraocular pressure (IOP) in adult patients with primary open-angle glaucoma.
  • The device offers a more efficient glaucoma procedure for patients and surgeons, and can be used standalone or in combination with cataract surgery to help control a glaucoma patient’s eye pressure while lessening their medication burden.
  • “I am constantly looking for minimally invasive treatment options for my patients that can deliver good results with less risk,” said Dr. Parul Khator, Georgia Eye Partners ophthalmologist and glaucoma specialist.
  • Georgia Eye Partners remains committed to serving patients throughout Greater Atlanta and Georgia by implementing the latest and greatest advanced glaucoma technologies and procedures.